Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 145 in heterozygous familial hypercholesterolemia
2012-001365-32Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of evolocumab in heterozygous familial hypercholesterolemia (HeFH) (3 arms), sponsored by Amgen. Primary endpoint: Percent change from baseline in LDL-C at week 12. Started Sep 2012; status: completed.
02
Drugs
evolocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on 2012-001365-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001365-32.